FDA Oncology Announcements

Fluoropyrimidine × Clear all

8 Announcements

FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma

Drugs: Imfinzi (durvalumab) · Anti-PD-L1 antibody, fluorouracil · Fluoropyrimidine
Condition: Gastrointestinal

FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer

Trial: SUNLIGHT
Drugs: LONSURF (trifluridine and tipiracil) · Fluoropyrimidine, bevacizumab · Anti-VEGFR antibody
Condition: Gastrointestinal

FDA approves neratinib for metastatic HER2-positive breast cancer

Trial: NALA
Drugs: NERLYNX (neratinib) · ERBB2 inhibitor, capecitabine · Fluoropyrimidine
Condition: Breast

FDA approves neratinib for metastatic HER2-positive breast cancer

Trial: NALA
Drugs: NERLYNX (neratinib) · ERBB2 inhibitor, capecitabine · Fluoropyrimidine
Condition: Breast

FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma

Drug: LONSURF (trifluridine/ tipiracil) · Fluoropyrimidine
Condition: Gastrointestinal

Uridine Triacetate

Drug: VISTOGARD granules (uridine triacetate) · Fluoropyrimidine
Condition: Other

Trifluridine/tipiracil

Drug: LONSURF (trifluridine/tipiracil) · Fluoropyrimidine
Condition: Gastrointestinal

FDA approves Taxotere for use in combination with cisplatin and fluorouracil for the induction treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck

Drugs: Taxotere Injection Concentrate (docetaxel) · Taxane, cisplatin · Platinum agent, fluorouracil · Fluoropyrimidine
Condition: Head & Neck